BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
详细信息 查看全文
- 作者：Kristel Kemper1 ; 9 ; Oscar Krijgsman1 ; 9 ; Xiangjun Kong1 ; Paulien Cornelissen-Steijger1 ; Aida Shahrabi1 ; Fleur Weeber1 ; Daphne L. van der Velden1 ; Onno B. Bleijerveld2 ; Thomas Kuilman1 ; Roel J.C. Kluin3 ; Chong Sun4 ; Emile E. Voest1 ; Young Seok Ju5 ; Ton N.M. Schumacher6 ; A.F. Maarten Altelaar2 ; 7 ; Ultan McDermott5 ; David J. Adams8 ; Christian U. Blank6 ; John B. Haanen6 ; Daniel S. Peeper1 ; d.peeper@nki.nl" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cell Reports
- 出版年：2016
- 出版时间：28 June 2016
- 年：2016
- 卷：16
- 期：1
- 页码：263-277
- 全文大小：5933 K
文摘
- •
Patient-derived xenograft (PDX) platform comprises 89 metastatic melanoma tumors
- •
Platform includes several pre-vemurafenib and vemurafenib-resistant PDXs
- •
Duplication of the BRAFV600E kinase domain is identified as a resistance mechanism
- •
Pan-RAF dimerization inhibitor LY3009120 eliminates melanoma cells with this duplication